Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

About this update from Biohaven Ltd.

NEW HAVEN - Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric , M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California , on Monday, January 13, 2025 , at 8:15 am (PT) . About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. Forward-looking Statements This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'continue', 'plan', 'will', 'believe', 'may', 'expect', 'anticipate' and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission , including within the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations'. The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact: Jennifer Porcelli Email: [email protected] Tel: +1 (201) 248-0741 Mike Beyer Email: [email protected] Tel: +1 (312) 961-2502 (C) 2025 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Biohaven Ltd.